查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
终末期肾病治疗方法（移植、透析）、地区（亚太、北美、MEA、欧洲、拉丁美洲）的市场规模、份额、趋势分析报告2022-2030
市场调查报告书
商品编码
1097153

终末期肾病治疗方法（移植、透析）、地区（亚太、北美、MEA、欧洲、拉丁美洲）的市场规模、份额、趋势分析报告2022-2030

End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (APAC, North America, MEA, Europe, Latin America), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 171 Pages | 商品交期: 2-10个工作天内

价格

终末期肾病的市场增长和趋势

据正观研究最新报告显示，全球终末期肾病市场在预测期内将达到12.9%的复合年增长率，到2030年预计将达到2616.4亿美元。

肾功能衰竭患者人数的增加、医院和急诊医疗中心的快速增加以及住院率的提高被认为是推动市场增长的因素。慢性肾脏病 (CKD) 是导致患者肾功能衰竭率增加的主要原因之一。据美国疾病控制与预防中心估计，美国有超过 3700 万人患有 CKD，全世界有超过 5 亿人（占世界人口的 12-18%）受到影响。因此，对透析和肾移植的需求正在增加。 COVID-19 流行病影响了医疗保健行业，ESRD 患者感染病毒的风险增加，因为他们需要经常去医院进行透析。在大多数国家，以中心为基础的血液透析是主要的肾臟替代疗法，是近 90% 的 ESRD 患者的选择。血液透析患者必须在医院至少逗留4小时，每週3次，并且会经常与医务人员和其他患者接触。这些因素会增加感染的风险。治疗肾衰竭的技术进步也是加速 ESRD 市场增长的因素。例如，可穿戴人工肾 (WAK) 技术的创新可以控制血压，改善血液中废物的清除，此外还可以减轻 ESRD 或 CKD 患者饮食不严格时对心臟的压力。该设备旨在让患者过上健康的生活，从而减少体重增加。因此，WAK 的技术进步有可能降低透析患者的死亡率并提高患者的生活质量。 WAK 原型由一家创新公司设计并获得专利，于 2016 年获得美国 FDA 批准用于人体临床试验。

终末期肾功能衰竭市场报告亮点

  • 2021年终末期肾病全球市场中，透析疗法以其易用性和应急便利性成为主流。
  • 该板块进一步细分为腹膜透析、血液透析、可穿戴人工肾。
  • 2021 年，亚太地区的销售额份额将最高，预计 2022 年至 2030 年的复合年增长率将进一步增长。
  • 这种增长是由于 CKD/ESRD 患者人数众多以及该大陆高血压和糖尿病的高发病率。

目录

第 1 章调查方法及范围

  • 市场细分和范围
    • 处理
    • 区域范围
    • 估计/预测时间线
  • 调查方法
  • 资讯采购
    • 购买的数据库:
    • GVR 内部数据库
    • 二次材料
    • 初步调查
    • 初步调查详情
  • 资讯或数据分析
    • 数据分析模型
  • 市场製定与验证
  • 型号详情
    • 产品流分析（模型一）
      • 方法一:产品流方法
    • 量价分析（模型二）
      • 方法二:量价分析
  • 二次材料清单
  • 主要来源列表
  • 缩写列表
  • 目的
    • 目的 1
    • 目的 2
    • 目的 3
    • 目的 4

第 2 章执行摘要

  • 市场展望
  • 细分市场展望
  • 竞争考虑

第 3 章终末期肾功能衰竭市场的变量、趋势和范围

  • 市场体系展望
    • 母公司市场展望
    • 辅助市场展望
  • 渗透率和增长前景映射
  • 产品管线分析
  • 用户视角分析
    • 消费者行为分析
    • 市场影响者分析
  • 关键最终用户列表
  • 监管框架
  • 市场动态
    • 市场促进因素分析
      • 糖尿病和高血压患病率增加
      • 技术先进的产品介绍
      • 越来越多的慢性肾病患者
    • 市场抑制因素分析
      • 并发症风险
      • 透析产品的严格监管政策
  • 终末期肾病:市场分析工具
    • 行业分析-Porter's
    • 害虫的 SWOT 分析

第 4 章终末期肾功能衰竭市场:细分分析，按治疗，2018-2030

  • 定义和范围
  • 2021 年和 2030 年治疗市场份额分析
  • 细分仪表板
  • 2018-2030 年全球终末期肾病市场（按治疗）
  • 2018-2030 年市场规模及预测及趋势分析
    • 透析
      • 2018-2030年透析市场
    • 移植
      • 2018-2030年移植市场

第 5 章终末期肾功能衰竭市场:区域市场分析，按治疗，2018-2030

  • 定义和范围
  • 2021 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场概况
  • 按因素（政治和法律、经济和技术）的 SWOT 分析
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 2016-2030 年市场规模和预测、数量和趋势分析
  • 北美
    • 2018-2030 年北美终末期肾功能衰竭市场
    • 美国
      • 2018-2030 年美国终末期肾功能衰竭市场
    • 加拿大
      • 2018-2030 年加拿大终末肾功能衰竭市场
  • 欧洲
    • 2018-2030 年欧洲终末期肾功能衰竭市场
    • 英国
      • 2018-2030 年英国终末期肾功能衰竭市场
    • 德国
      • 2018-2030年德国终末期肾病市场
    • 法国
      • 2018-2030年法国终末期肾病市场
    • 意大利
      • 2018-2030 年意大利终末期肾病市场
    • 西班牙
      • 2018-2030 年西班牙终末期肾功能衰竭市场
  • 亚太地区
    • 2018-2030 年亚太地区终末期肾功能衰竭市场
    • 日本
      • 2018-2030年日本终末期肾病市场
    • 中国（大陆）
      • 2018-2030年中国（大陆）终末期肾功能衰竭市场
    • 印度
      • 2018-2030 年印度终末期肾功能衰竭市场
    • 澳大利亚
      • 2018-2030 年澳大利亚终末肾功能衰竭市场
    • 韩国
      • 2018-2030 年韩国终末期肾病市场
  • 拉丁美洲
    • 2018-2030 年拉丁美洲终末期肾功能衰竭市场
    • 巴西
      • 2018-2030 年巴西终末期肾功能衰竭市场
    • 墨西哥
      • 2018-2030 年墨西哥终末期肾功能衰竭市场
    • 阿根廷
      • 2018-2030 年阿根廷终末肾衰竭市场
    • 哥伦比亚
      • 2018-2030 年哥伦比亚终末期肾病市场
  • 多边环境协定
    • 2018-2030 年 MEA 终末期肾功能衰竭市场
    • 南非
      • 2018-2030 年南非终末期肾功能衰竭市场
    • 沙特阿拉伯
      • 2018-2030 年沙特阿拉伯终末期肾功能衰竭市场
    • 阿拉伯联合酋长国
      • 2018-2030 年阿拉伯联合酋长国终末期肾功能衰竭市场

第 6 章终末期肾功能衰竭市场-竞争分析

  • 主要市场参与者的近期趋势和影响分析
    • Nipro Corporation
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要客户
    • 2021 年主要公司的市场份额分析
    • 重大交易和战略联盟
      • 推出新产品
      • 扩展
      • 获取
      • 营销与推广
    • 市场进入策略
  • 上市公司
    • 公司市场分析
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 私人公司
    • 主要初创企业列表
    • 区域网络图
    • 公司市场分析
  • 公司简介
    • Medtronic
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Fresenius Medical Care AG & Co. KGaA
      • 公司简介
      • 财务表现
      • 产品/服务基准
      • 战略举措
    • B. Brown Melsungen AG
      • 公司简介
      • 财务表现
      • 产品/服务基准
    • Baxter International, Inc.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Asahi Kasei Medical Co., Ltd.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Cantel Medical
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • BD
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Nikkiso Co., Ltd.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • JMS Co. Ltd.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
Product Code: GVR-4-68038-434-5

End Stage Renal Disease Market Growth & Trends:

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period, according to a new report by Grand View Research, Inc. Increasing number of patients suffering from kidney failure, rapid increase in the volume of hospitals & urgent care centers, and growing hospital admission rates are among the few factors propelling the market growth. Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients. According to the CDC, it is estimated that more than 37 million people in the U.S. suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected. As a result, increasing the demand for dialysis or kidney transplant. The COVID-19 pandemic has impacted the healthcare industry and people suffering from ESRD are at a higher risk of contracting this virus, as they have to visit the hospitals often for dialysis. Center-based hemodialysis is the main renal replacement medium in most countries, with almost 90% of the ESRD population opting for it. Hemodialysis patients have to stay in hospitals for 4 hours minimum, 3 times a week, and come in frequent contact with the medical staff and other patients. All these factors increase their risk of infection. Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD. For instance, the innovation of Wearable Artificial Kidney (WAK) technologies, a portable dialysis device designed to enable patients to live a healthier life as it controls blood pressure, improves clearance of wastes from the blood, and allows ESRD or CKD patients to a less strict diet, and results in lower fluid weight gain in addition to lowered stress on the heart. Thus, technical advancements in WAK have the potential to reduce mortality in dialysis patients, which thereby improves an ESRD patient's quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016.

End Stage Renal Disease Market Report Highlights:

  • The dialysis segment dominated the global ESRD market in 2021 owing to its ease of use and emergency convenience
  • this segment is further sub-segmented into peritoneal, hemodialysis, and wearable artificial kidney
  • The Asia Pacific region dominated the market with the highest revenue share in 2021 and will expand further at the fastest CAGR from 2022 to 2030
  • This growth can be attributed to the large population of patients with CKD/ESRD, and the greater incidence of hypertension and diabetes in the continent

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Treatment
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume price analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2. Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3. End Stage Renal Disease Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis
  • 3.4 User Perspective Analysis
    • 3.4.1 Consumer Behavior Analysis
    • 3.4.2 Market Influencer Analysis
  • 3.5 List Of Key End Users
  • 3.6 Regulatory Framework
  • 3.7 Market Dynamics
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Growing Prevalence Of Diabetes And Hypertension
      • 3.7.1.2 Introduction Of Technologically Advanced Products
      • 3.7.1.3 Increasing Number Of Patients Suffering From Chronic Kidney Disease
    • 3.7.2 Market Restraints Analysis
      • 3.7.2.1 Risk Of Complications
      • 3.7.2.2 Stringent Regulatory Policies For Dialysis Products
  • 3.8 End Stage Renal Disease: Market Analysis Tools
    • 3.8.1 Industry Analysis - Porter's
    • 3.8.2 Swot Analysis, By Pest

Chapter 4. End Stage Renal Disease Market: Segment Analysis, By Treatment, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Treatment Market Share Analysis, 2021 & 2030
  • 4.3 Segment Dashboard
  • 4.4 Global End Stage Renal Disease Market, by Treatment, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 DIALYSIS
      • 4.5.1.1 Dialysis market, 2018 - 2030 (USD Million)
    • 4.5.2 TRANSPLANT
      • 4.5.2.1 Transplant market, 2018 - 2030 (USD Million)

Chapter 5. End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2018 - 2030 (USD Million)

  • 5.1 Definition & Scope
  • 5.2 Regional Market Share Analysis, 2021 & 2030
  • 5.3 Regional Market Dashboard
  • 5.4 Regional Market Snapshot
  • 5.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 5.5.1 North America
    • 5.5.2 Europe
    • 5.5.3 Asia Pacific
    • 5.5.4 Latin America
    • 5.5.5 Middle East and Africa
  • 5.6 Market Size, & Forecasts, Volume and Trend Analysis, 2016 to 2030
  • 5.7 North America
    • 5.7.1 North America End Stage Renal Disease Market, 2018 - 2030 (USD Million)
    • 5.7.2 U.S.
      • 5.7.2.1 U.S. end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.7.3 Canada
      • 5.7.3.1 Canada end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.8 Europe
    • 5.8.1 Europe End Stage Renal Disease Market, 2018 - 2030 (USD Million)
    • 5.8.2 U.K.
      • 5.8.2.1 U.K. end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.3 Germany
      • 5.8.3.1 Germany end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.4 France
      • 5.8.4.1 France end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.5 Italy
      • 5.8.5.1 Italy end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.8.6 Spain
      • 5.8.6.1 Spain end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.9 Asia Pacific
    • 5.9.1 Asia Pacific end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.9.2 Japan
      • 5.9.2.1 Japan end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.3 China (Mainland)
      • 5.9.3.1 China (Mainland) end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.4 India
      • 5.9.4.1 India end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.5 Australia
      • 5.9.5.1 Australia end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.9.6 South Korea
      • 5.9.6.1 South Korea end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.10 Latin America
    • 5.10.1 Latin America end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.10.2 Brazil
      • 5.10.2.1 Brazil end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.3 Mexico
      • 5.10.3.1 Mexico end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.4 Argentina
      • 5.10.4.1 Argentina end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.10.5 Colombia
      • 5.10.5.1 Colombia end stage renal disease market, 2018 - 2030 (USD Million)
  • 5.11 MEA
    • 5.11.1 MEA end stage renal disease Market, 2018 - 2030 (USD Million)
    • 5.11.2 South Africa
      • 5.11.2.1 South Africa end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.11.3 Saudi Arabia
      • 5.11.3.1 Saudi Arabia end stage renal disease market, 2018 - 2030 (USD Million)
    • 5.11.4 UAE
      • 5.11.4.1 UAE end stage renal disease market, 2018 - 2030 (USD Million)

Chapter 6. End Stage Renal Disease Market - Competitive Analysis

  • 6.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.1.1 Nipro Corporation
  • 6.2 Company Categorization
    • 6.2.1 Innovators
    • 6.2.2 Market Leaders
  • 6.3 Vendor Landscape
    • 6.3.1 Key Customers
    • 6.3.2 Key Company Market Share Analysis, 2021
    • 6.3.3 Major Deals And Strategic Alliances
      • 6.3.3.1 New Product Launch
      • 6.3.3.2 Expansion
      • 6.3.3.3 Acquisition
      • 6.3.3.4 Marketing & Promotions
    • 6.3.4 Market Entry Strategies
  • 6.4 Public Companies
    • 6.4.1 Company Market Position Analysis
    • 6.4.2 Competitive Dashboard Analysis
      • 6.4.2.1 Market Differentiators
  • 6.5 Private Companies
    • 6.5.1 List of Key Emerging Companies
    • 6.5.2 Regional Network Map
    • 6.5.3 Company Market Position Analysis
  • 6.6 Company Profiles
    • 6.6.1 Medtronic
      • 6.6.1.1 Company Overview
      • 6.6.1.2 Financial Performance
      • 6.6.1.3 Product Benchmarking
      • 6.6.1.4 Strategic Initiatives
    • 6.6.2 Fresenius Medical Care AG & Co. KGaA
      • 6.6.2.1 Company Overview
      • 6.6.2.2 Financial Performance
      • 6.6.2.3 Product/Service Benchmarking
      • 6.6.2.4 Strategic Initiatives
    • 6.6.3 B. Braun Melsungen AG
      • 6.6.3.1 Company Overview
      • 6.6.3.2 Financial Performance
      • 6.6.3.3 Product/Service Benchmarking
    • 6.6.4 Baxter International, Inc.
      • 6.6.4.1 Company Overview
      • 6.6.4.2 Financial Performance
      • 6.6.4.3 Product Benchmarking
      • 6.6.4.4 Strategic Initiatives
    • 6.6.5 Asahi Kasei Medical Co., Ltd.
      • 6.6.5.1 Company Overview
      • 6.6.5.2 Financial Performance
      • 6.6.5.3 Product Benchmarking
      • 6.6.5.4 Strategic Initiatives
    • 6.6.6 Cantel Medical
      • 6.6.6.1 Company Overview
      • 6.6.6.2 Financial Performance
      • 6.6.6.3 Product Benchmarking
      • 6.6.6.4 Strategic Initiatives
    • 6.6.7 BD
      • 6.6.7.1 Company Overview
      • 6.6.7.2 Financial Performance
      • 7.6.7.3 Product Benchmarking
      • 6.6.7.4 Strategic Initiatives
    • 6.6.8 Nikkiso Co., Ltd.
      • 6.6.8.1 Company Overview
      • 6.6.8.2 Financial Performance
      • 6.6.8.3 Product Benchmarking
      • 6.6.8.4 Strategic Initiatives
    • 6.6.9 JMS Co. Ltd.
      • 6.6.9.1 Company Overview
      • 6.6.9.2 Financial Performance
      • 6.6.9.3 Product Benchmarking
      • 6.6.9.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 Canada end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 Europe end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 8 Europe end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.K. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Germany end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 France end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Italy end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Spain end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Russia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Asia Pacific end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 China end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 India end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 South Korea end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Australia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Japan end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Singapore end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Latin America end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 24 Latin America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Brazil end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Mexico end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Argentina end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Colombia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Middle East & Africa end stage renal disease market, by country, 2018 - 2030 (USD Million)
  • Table 30 Middle East & Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 South Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 South Arabia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 UAE end stage renal disease market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 End stage renal disease market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2021)
  • Fig. 10 Segment Outlook
  • Fig. 11 Strategy framework
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Consumer behavior analysis
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 18 End Stage Renal Disease market: Treatment movement analysis
  • Fig. 19 Segment dashboard
  • Fig. 20 End Stage Renal Disease market treatment outlook: Key takeaways
  • Fig. 21 Dialysis market, 2018 - 2030 (USD Million)
  • Fig. 22 Transplantation market, 2018 - 2030 (USD Million)
  • Fig. 23 End Stage Renal Disease market: End use movement analysis
  • Fig. 24 Regional outlook, 2021 & 2030
  • Fig. 25 Regional market dashboard
  • Fig. 26 Regional market place: Key takeaways
  • Fig. 27 North America, SWOT, by PEST
  • Fig. 28 Europe, SWOT, by PEST
  • Fig. 29 Asia Pacific, SWOT, by PEST
  • Fig. 30 Latin America, SWOT, by PEST
  • Fig. 31 Middle East and Africa, SWOT, by PEST
  • Fig. 32 North America end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 36 U.K. End Stage Renal Disease market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 38 France end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 43 China (Mainland) end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 44 India end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 51 Colombia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE end stage renal disease market, 2018 - 2030 (USD Million)
  • Fig. 56 Company market share analysis, 2021
  • Fig. 57 Strategy mapping
  • Fig. 58 Market differentiators
  • Fig. 59 Regional network map